Keywords: topotecan, 1st-line, ovarian, cancer, drug, smithkline, beecham

Topotecan As 1st-Line Ovarian Cancer Drug

Article | 13 November 1995

Print This

SmithKline Beecham is starting a major trial of its topoisomerase I inhibitor Hycamtin (topotecan), in combination with cisplatin, for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in